Abstract:

Introduction and Target: The development of brain metastases is frequently observed in lung carcinomas and increases mortality. Our study aims to evaluate the factors that affect the development of brain metastasis in patients monitored with the diagnosis of lung cancer and to determine the survivors after brain metastasis. Method and Requirements: 72 patients diagnosed with lung cancer in January–December 2017, who did not detect brain metastases at the moment of diagnosis and who developed brain metastases in their follow-up were taken to study. Adenocarcinoma was detected at 40.3% while small cell lung cancer was 31.9%, squamous cell cancer was 26.4%. At the time of diagnosis, 30.6 percent of patients were in stage IVB, 29.2 percent in stage IIIB and 18.1 percent in stage IIIA group. There were a total of 5 (6.9%) patients in stage I and II groups. In 66.7 percent of patients, N2 constipation was observed, while in 23.6 percent, N3 constipation was observed. The first diagnosis was not found in 63.9% of distant metastasis patients. From the moment of the diagnosis, the period of development of brain metastases was 11.9 ± 8.5 months. After the development of brain metastasis, the life of the patients was 3,77 ± 4,0 months. Only 8.3 percent of patients (n: 6) are still alive. All living patients have been diagnosed with adenocarcinoma. INTRODUCTION AND RESULTATION: In our study, despite sufficient treatment responses in primary tumor, it was observed that patients develop brain metastases within approximately a year and caused them to lose their lives within two months. Mediastinal lymph nodus retention, local advanced and metastatic stages of disease and adeno cancer histology are among the effective factors in the development of brain metastasis in lung cancer.

Keywords: